Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
Holding LEGN?
Track your performance easily
LEGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$38.60 - $70.78
Previous Close$49.27
Volume984.05K
Average Volume (3M)943.59K
Market Cap
$8.58B
Enterprise Value$8.13B
Total Cash (Recent Filing)$1.28B
Total Debt (Recent Filing)$383.94M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Nov 18, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding181,911,035
10 Day Avg. Volume1,035,092
30 Day Avg. Volume943,591
Standard Deviation0.14
R-Squared0.00140
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)7.16
Price to Sales (P/S)107.25
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue154.00
Enterprise Value/Gross Profit57.70
Enterprise Value/Ebitda-35.73
Forecast
1Y Price Target
$80.56Price Target Upside63.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Legend Biotech News
PremiumCompany Announcements
Legend Biotech’s CARVYKTI® Revolutionizes Multiple Myeloma Treatment
PremiumCompany Announcements
Legend Biotech Announces Key AGM Proposals
PremiumCompany Announcements
Legend Biotech’s New Cancer Drug Wins Approval
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCarvykti has the best launch among approved cell therapies due to its best-in-class efficacy, expanding manufacturing capacity, and improved manufacturing efficiency.
Market DemandCARVYKTI launch metrics are trending favorably, with high demand in the second-line multiple myeloma setting.
Regulatory ApprovalsCARVYKTI receives regulatory approval in China.
Bears Say
Drug PricingBranded Rx drug prices in China are typically significantly lower and the market is predominantly self-pay, tempering the potential for rapid CARVYKTI sales growth.
Legislative And Regulatory IssuesThe BIOSECURE Act is an overhang now that GenScript is under scrutiny by Congress.
Market CompetitionPreliminary data from Anito-Cel's pivotal iMMagine-1 suggests its efficacy is comparable to Carvykti but safer than both Carvykti and Abecma.
---
Ownership Overview
0.00%
Insiders
19.15% Mutual Funds
22.00% Other Institutional Investors
58.85% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $38.60 and its highest was $70.78 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Currently, no data Available
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Nov 18, 2024 which is in 50 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on Aug 09, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.287 by $0.237.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is -$0.34.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 181,911,040 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.287. Following the earnings report the stock price went down -1.775%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Among the largest hedge funds holding Legend Biotech Corporation’s share is RA Capital Management. It holds Legend Biotech Corporation’s shares valued at 332M.
---
Legend Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.56 (63.51% Upside)
$80.56 (63.51% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 350.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.54%
12-Months-Change
Fundamentals
Return on Equity
-22.21%
Trailing 12-Months
Asset Growth
-6.86%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Its other pipeline products include LB1910, LB1909, LB1903, and others. Geographically, the company generates a majority of its revenue from North America.
---
LEGN Earnings Call
Q2 2024
0:00 / 0:00
---
LEGN Stock 12 Month Forecast
Average Price Target
$80.56
▲(63.51% Upside)
Technical Analysis
Best Analysts Covering LEGN
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+26.75%
reiterated a buy rating 5 months ago
Copying Matthew Harrison's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +26.75% per trade.
---